136 related articles for article (PubMed ID: 9696397)
1. Prognostic relevance of cathepsin D detection in micrometastatic cells in the bone marrow of patients with primary breast cancer.
Solomayer EF; Diel IJ; Meyberg GC; Gollan C; Bode S; Wallwiener D; Bastert G
Breast Cancer Res Treat; 1998 May; 49(2):145-54. PubMed ID: 9696397
[TBL] [Abstract][Full Text] [Related]
2. Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer.
Solomayer EF; Diel IJ; Wallwiener D; Bode S; Meyberg G; Sillem M; Gollan C; Kramer MD; Krainick U; Bastert G
Br J Cancer; 1997; 76(6):812-8. PubMed ID: 9310251
[TBL] [Abstract][Full Text] [Related]
3. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.
Diel IJ; Kaufmann M; Costa SD; Holle R; von Minckwitz G; Solomayer EF; Kaul S; Bastert G
J Natl Cancer Inst; 1996 Nov; 88(22):1652-8. PubMed ID: 8931609
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of cathepsin D in breast cancer: comparison of immunohistochemical and immunoradiometric detection methods.
Göhring UJ; Scharl A; Thelen U; Ahr A; Crombach G; Titius BR
J Clin Pathol; 1996 Jan; 49(1):57-64. PubMed ID: 8666688
[TBL] [Abstract][Full Text] [Related]
5. [Micrometastatic cells in the bone marrow of patients with breast carcinoma].
Diel IJ; Solomayer EF; Bastert G
Radiologe; 2000 Aug; 40(8):681-7. PubMed ID: 11006937
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of cathepsin-D expression in node-positive breast carcinoma: an immunohistochemical study.
Têtu B; Brisson J; Côté C; Brisson S; Potvin D; Roberge N
Int J Cancer; 1993 Sep; 55(3):429-35. PubMed ID: 8397164
[TBL] [Abstract][Full Text] [Related]
7. A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol.
Pujol P; Maudelonde T; Daures JP; Rouanet P; Brouillet JP; Pujol H; Rochefort H
Cancer; 1993 Mar; 71(6):2006-12. PubMed ID: 8443752
[TBL] [Abstract][Full Text] [Related]
8. Cathepsin D: an independent prognostic factor for metastasis of breast cancer.
Spyratos F; Maudelonde T; Brouillet JP; Brunet M; Defrenne A; Andrieu C; Hacene K; Desplaces A; Rouëssé J; Rochefort H
Lancet; 1989 Nov; 2(8672):1115-8. PubMed ID: 2572846
[TBL] [Abstract][Full Text] [Related]
9. Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer.
Ravdin PM; Tandon AK; Allred DC; Clark GM; Fuqua SA; Hilsenbeck SH; Chamness GC; Osborne CK
J Clin Oncol; 1994 Mar; 12(3):467-74. PubMed ID: 8120545
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of cathepsin D as prognostic predictor in breast cancer.
Barbi GP; Margallo E; Margiocco M; Paganuzzi M; Marroni P; Costanzi B; Gatteschi B; Tanara G; Spina B; Nicolò G
Oncology; 1994; 51(4):329-33. PubMed ID: 8208515
[TBL] [Abstract][Full Text] [Related]
11. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients.
Foekens JA; Look MP; Bolt-de Vries J; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Jan; 79(2):300-7. PubMed ID: 9888472
[TBL] [Abstract][Full Text] [Related]
12. Stromal cell cathepsin D expression and long-term survival in breast cancer.
Joensuu H; Toikkanen S; Isola J
Br J Cancer; 1995 Jan; 71(1):155-9. PubMed ID: 7819033
[TBL] [Abstract][Full Text] [Related]
13. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer.
Thorpe SM; Rochefort H; Garcia M; Freiss G; Christensen IJ; Khalaf S; Paolucci F; Pau B; Rasmussen BB; Rose C
Cancer Res; 1989 Nov; 49(21):6008-14. PubMed ID: 2790815
[TBL] [Abstract][Full Text] [Related]
14. Cathepsin D in primary breast carcinoma: adverse prognosis is associated with expression of cathepsin D in stromal cells.
O'Donoghue AE; Poller DN; Bell JA; Galea MH; Elston CW; Blamey RW; Ellis IO
Breast Cancer Res Treat; 1995; 33(2):137-45. PubMed ID: 7749141
[TBL] [Abstract][Full Text] [Related]
15. Comparative prognostic value of Cathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma.
Göhring UJ; Scharl A; Thelen U; Ahr A; Crombach G
Anticancer Res; 1996; 16(2):1011-8. PubMed ID: 8687092
[TBL] [Abstract][Full Text] [Related]
16. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.
Isola J; Weitz S; Visakorpi T; Holli K; Shea R; Khabbaz N; Kallioniemi OP
J Clin Oncol; 1993 Jan; 11(1):36-43. PubMed ID: 8093367
[TBL] [Abstract][Full Text] [Related]
17. Lack of prognostic value of cathepsin D levels for predicting short term outcomes of breast cancer patients.
Ravdin PM; de Moor CA; Hilsenbeck SG; Samoszuk MK; Vendely PM; Clark GM
Cancer Lett; 1997 Jun; 116(2):177-83. PubMed ID: 9215861
[TBL] [Abstract][Full Text] [Related]
18. [Expression of cathepsin D in breast cancer and its clinical and histopathological correlations].
Ramírez-Ortega MC; Frías-Mendívil M; Delgado-Chávez R; Meneses-García A; Carrillo-Hernández JF; Ramírez-Ugalde MT; Zeichner-Gancz I
Rev Invest Clin; 1997; 49(5):361-8. PubMed ID: 9527695
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy.
Braun S; Cevatli BS; Assemi C; Janni W; Kentenich CR; Schindlbeck C; Rjosk D; Hepp F
J Clin Oncol; 2001 Mar; 19(5):1468-75. PubMed ID: 11230493
[TBL] [Abstract][Full Text] [Related]
20. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
